Galapagos initiates second Proof of Mechanism clinical study in GSK alliance

  • Following successful outcome of first-in-human trial for GLPG0778
  • Phase I study measures effect on biomarker in healthy volunteers 

Mechelen, Belgium; 11 May 2011 – Galapagos NV (Euronext: GLPG) announced today that it has initiated a second Phase I Proof of Mechanism study in its immuno-inflammation alliance with GlaxoSmithKline.  This new study follows the positive outcome of the first-in-human trial conducted for GLPG0778, which showed an acceptable safety and pharmacokinetics profile in healthy volunteers for one-week dosing and an initial biomarker response.  The Proof of Mechanism study is aimed at assessing GLPG0778’s effect on a specific target in healthy volunteers.

Galapagos plans to conduct the multiple ascending dose study in 45 healthy volunteers using five two-week dosing regimens.  In this Proof of Mechanism study, GPLG0778’s ability to suppress an induced inflammatory response in healthy volunteers will be evaluated.  In addition to measuring the biomarker response, the safety, tolerability and pharmacokinetics of candidate drug GLPG0778 will be assessed further.  Galapagos aims to report the study results in the fourth quarter of 2011.  GSK has an exclusive option to in-license this compound. 

“With the initiation of this study, we could demonstrate clinical proof of mechanism for GLPG0778 this year,” said Onno van de Stolpe, CEO of Galapagos.  “Together with two other compounds in development, we have multiple programs capable of delivering in the immuno-inflammation alliance with GSK.”

About Galapagos’ immuno-inflammation alliance with GlaxoSmithKline
GSK and Galapagos initiated an alliance to discover and develop disease-modifying drugs for GSK’s global R&D organization in June 2006.  GSK and Galapagos expanded the alliance on three occasions to include additional targets.  Following the latest expansion in December 2009 and, subject to achievement of milestones Galapagos has the potential to receive more than €200 million, plus up to double-digit royalties from GSK.  GSK has an exclusive option to further develop and commercialize these compounds on a worldwide basis.  Since the start of the immuno-inflammation alliance, Galapagos has received more than €60 million in payments from GSK.

About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action.  The Company is progressing one of the largest pipelines in biotech, with six programs in development and over 50 discovery programs.  Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to receive up to €2.5 billion in downstream milestones, plus royalties.  The Galapagos Group has over 800 employees and operates facilities in seven countries, with global headquarters in Mechelen, Belgium.  More info at:


Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240

This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.